FDA Approves EOVIST — Bayer HealthCare Pharmaceuticals Inc.

# FDA Approves Bayer's EOVIST for Hepatic Imaging The U.S. Food and Drug Administration has approved Bayer HealthCare Pharmaceuticals' EOVIST (gadoxetate disodium), an intravenous contrast agent designed to enhance magnetic resonance imaging of the liver, positioning the company to capture market share in the hepatic imaging segment. The approval expands Bayer's diagnostic imaging portfolio and offers clinicians an advanced tool for detecting liver lesions and assessing hepatic function in patients with suspected liver disease.